Deutsche Märkte öffnen in 7 Stunden 19 Minuten
  • Nikkei 225

    27.465,66
    +83,10 (+0,30%)
     
  • Dow Jones 30

    33.978,08
    +28,68 (+0,08%)
     
  • BTC-EUR

    21.844,47
    +453,04 (+2,12%)
     
  • CMC Crypto 200

    539,52
    +22,52 (+4,35%)
     
  • Nasdaq Compositive

    11.621,71
    +109,31 (+0,95%)
     
  • S&P 500

    4.070,56
    +10,13 (+0,25%)
     

Is This Biotech Stock a Buy Following a Landmark Approval?

Is This Biotech Stock a Buy Following a Landmark Approval?

Provention Bio (NASDAQ: PRVB) is a small-cap biotech whose shares have doubled in the past three months. The company can thank the expected and eventual approval of Tzield for that performance. In mid-November, Tzield became the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for the delay of the onset of type 1 diabetes (T1D) in at-risk patients.